Enzon Pharmaceuticals Files 2024 Proxy Statement

TL;DR

Enzon Pharma's proxy statement is out for the 9/26 shareholder meeting. Vote wisely.

AI Summary

Enzon Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on August 8, 2024, for its annual meeting of stockholders scheduled for September 26, 2024. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information regarding the company's leadership, executive pay, and voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing information to shareholders and does not indicate any immediate financial or operational risks.

Key Players & Entities

• ENZON PHARMACEUTICALS, INC. (company) — Registrant
• 0001104659-24-087308.txt (document) — Filing identifier
• 20240808 (date) — Filing date
• 20240926 (date) — Annual meeting date

FAQ

Filing Documents

• tm2420299-2_def14a.htm (DEF 14A) — 237KB
• lg_enzonpharma-4c.jpg (GRAPHIC) — 20KB
• px_24enzonproxy01pg01-bw.jpg (GRAPHIC) — 383KB
• px_24enzonproxy01pg02-bw.jpg (GRAPHIC) — 302KB
• 0001104659-24-087308.txt ( ) — 1210KB

From the Filing

DEF 14A 1 tm2420299-2_def14a.htm DEF 14A tm2420299-2_def14a - none - 2.7656362s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 ENZON PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 20 Commerce Drive, Suite 135 Cranford, New Jersey 07016 (732) 980-4500 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, SEPTEMBER 26, 2024 To our stockholders: The 2024 annual meeting of stockholders (the "2024 Annual Meeting") of Enzon Pharmaceuticals, Inc., a Delaware corporation, will be held at 800 Capitol St., Suite 2400, Houston, Texas 77002 on Thursday, September 26, 2024 at 10:30 a.m., local time, for the following purposes: 1. to elect three directors, each for a one-year term expiring at our next annual meeting of stockholders and until such director's successor is elected and qualified (Proposal No. 1); 2. to ratify the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 (Proposal No. 2); 3. to approve, on an advisory basis, the compensation of our named executive officer (Proposal No. 3); 4. to ratify an amendment (the "Second Amendment") to the Section 382 Rights Agreement (the "Rights Agreement") by and between us and Continental Stock Transfer & Trust Company, to extend the Final Expiration Date (as defined in the Rights Agreement) to the close of business on March 31, 2025 (Proposal No. 4); and 5. to transact such other matters as may properly come before the 2024 Annual Meeting or any adjournment or postponement thereof. Only holders of record of our Common Stock as of the close of business on August 7, 2024, the record date, are entitled to notice of and to vote at the 2024 Annual Meeting. Whether or not you plan to attend the 2024 Annual Meeting, your vote is important. To assure your representation at the meeting, please vote by signing and dating the enclosed proxy card and returning it promptly in the enclosed postage-paid envelope or by submitting voting instructions via the Internet at www.cstproxyvote.com. Sending in your proxy or submitting voting instructions via the Internet will not prevent you from voting in person at the 2024 Annual Meeting. If you vote in person by ballot at the 2024 Annual Meeting, that vote will revoke any prior proxy or voting instructions that you have submitted. By Order of the Board of Directors, /s/ Richard L. Feinstein Richard L. Feinstein Chief Executive Officer, Chief Financial Officer and Secretary Cranford, New Jersey August 8, 2024 IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON SEPTEMBER 26, 2024 This Proxy Statement, the Proxy Card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are available online at: https://www.cstproxy.com/enzon/2024 20 Commerce Drive, Suite 135 Cranford, New Jersey 07016 (732) 980-4500 PROXY STATEMENT Enzon Pharmaceuticals, Inc. is furnishing this proxy statement to our stockholders of record as of the close of business on August 7, 2024 (the "Record Date") in connection with our solicitation of proxies for use at the annual meeting of stockholders to be held at 800 Capitol St., Suite 2400, Houston, Texas 77002 on Thursday, September 26, 2024 at 10:30 a.m., local time and any adjournment(s), postponement(s) or other delays thereof (the "2024 Annual Meeting"). References in this proxy statement to the "Company," "our company," "we," "us," "our" and similar terms mean Enzon Pharmaceuticals, Inc. The accompanying proxy is solicited by our Board of Directors (our "Board") and is revocable by the stockholder any time before it is voted at the 2024 Annual Meeting, as described below. We have elected to take advantage of the U.S. Securities and Exchange Commission's (the "SEC") "notice and access" rule that allows us to furnish proxy materials to stockholders online. On or about August 16, 2024, we will mail to our stockholders of record as of the close of business on the Record Date either (i) a Notice of Internet Availability of Proxy Materials containing instructions on how to access our proxy materials online and how t

View Full Filing

View this DEF 14A filing on SEC EDGAR